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OBJECTIVE — Recent studies have proven the favorable effects of angiotensin receptor
blockers (ARBs) on cardiovascular and renal disorders. However, determinants of the response
to ARBs remain unclear. We substantiated the hypothesis that genetic variants of the renin-
angiotensin system (RAS) have signiﬁcant impacts on the response to ARBs.
RESEARCH DESIGN AND METHODS — Subjects comprised 231 consecutively en-
rolledhypertensiveindividualsincluding45type2diabeticsubjects.Fivegeneticvariantsofthe
RAS,i.e.,renin(REN)C-5312T,ACEinsertion/deletion,angiotensinogenM235T,angiotensinII
type 1 receptor A1166C, and angiotensin II type 2 receptor C3123A were assayed by PCR and
restriction fragment-length polymorphism. A dose of 40–160 mg/day of valsartan was admin-
istered for 3 months as a monotherapy.
RESULTS — Changes in diastolic blood pressure signiﬁcantly differed between genotypes of
REN C-5312T: 10.7-mmHg reduction (from 95.9  12.9 to 85.2  11.4) in CC versus 7.0-
mmHg reduction (from 94.7  14.0 to 87.7  12.6) in CT/TT (P  0.02 for interactive effects
of valsartan and genotype). Responder rates also differed between the genotypes: 72.8% in CC
versus 58.0% in CT/TT (P  0.03). Univariate analysis indicated a signiﬁcant association of
response to valsartan with blood pressure, diabetes, plasma aldosterone concentration, and CC
homozygotesofRENC-5312T.Finally,multiplelogisticregressionanalysisrevealedthatsystolic
blood pressure, CC homozygotes of REN C-5312T, and diabetes were independent predictors
for responders with odds ratios (95% CI) of 2.49 (1.41–4.42), 2.03 (1.10–3.74), and 0.48
(0.24–0.96), respectively.
CONCLUSIONS — This study provides strong support that a genetic variant of REN
C-5312T and diabetes contribute to the effects of ARBs and are independent predictors for
responder. Thus, in treatment of hypertension with ARBs, a new possibility for personalized
medicine has been shown.
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T
he renin-angiotensin system (RAS)
plays major roles in blood pressure
regulation and electrolyte metabo-
lism (1) and pivotal roles in the patho-
physiology of cardiovascular, renal, and
metabolic conditions (2,3). Genetic vari-
antsofthissystemhavebeendevelopedto
test their association with cardiovascular
and renal conditions. An ACE insertion/
deletion polymorphism has been associ-
ated with ischemic heart disease (4) and
the development of stage 5 chronic kid-
ney disease (5). Angiotensinogen M235T
hasbeenassociatedwiththedevelopment
of hypertension (6). Angiotensin II type 1
(AT1) receptor A1166C has been associ-
ated with the development of hyperten-
sion and ischemic heart disease (7).
Recently, a number of large-scale pro-
spectivestudieshaveproventhefavorable
effects of blockade of the RAS on cardio-
vascularandrenalconditions(8,9).How-
ever, the association between genetic
variants of the RAS and effects of angio-
tensin II receptor blockers is still unclear
(10) and must be well elucidated. There-
fore, we substantiated the hypothesis that
some variants of the RAS have inﬂuences
on the effects of single administration of
valsartan and analyzed determinants of
responders to angiotensin II receptor
blockers including the genetic variants.
RESEARCH DESIGN AND
METHODS— We enrolled 233 con-
secutive hypertensive patients from our
outpatient clinic in the study, and 231
subjects completed the study. They con-
sistedof101(43%)menwithmeanSD
age, BMI, glucose level, A1C, LDL, and
estimated glomerular ﬁltration rate
(eGFR) of 64.6  12.6 years, 24.6  3.9
kg/m
2, 107.4  19.8 mg/dl, 5.46 
0.87%, 117.1  28.7 mg/dl, and 72.5 
18.3ml/minper1.73m
2,respectively.All
subjects were Japanese inhabiting Ho-
kuriku, a region of Japan. Subjects aged
20 years old and those with secondary
hypertension, target organ disease, severe
organ failure, and acute-phase disorders
were excluded. All subjects had not taken
any antihypertensive or antidyslipidemic
agents for at least 1 week before the ﬁrst
sampling for the study, and home blood
pressure was measured to exclude sub-
jects with white coat hypertension. In the
clinic, with the subject in a sitting posi-
tion, blood pressure was taken from the
left arm at least three times repeatedly us-
ing an automated digital device (ES-H51;
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by as much time as practical. If readings
varied 5 mmHg, additional readings
were taken until the last two were close.
Diabetic subjects, 19.5% of the total sub-
jects,continuedtoreceivetheirusualcare
for diabetes. A target A1C level of 6.5%
wasrecommendedforallsubjects.Diabe-
teswasdiagnosedaccordingtothecriteria
of the World Health Organization. Dys-
lipidemia was diagnosed according to the
criteria of the International Diabetes Fed-
eration. Estimated glomerular ﬁltration
rate (eGFR) was calculated according to
the formula for Japanese subjects: eGFR
(milliliters per minute per 1.73 m
2) 
194  creatinine
1.094  age
0.287 (
0.739,forwomen).BMIwascalculatedas
the weight in kilograms divided by the
squareofheightinmeters.Arterialhyper-
tension was deﬁned as systolic blood
pressure (SBP) of 140 mmHg or dia-
stolic blood pressure (DBP) of 90
mmHg with the subject in the sitting po-
sition on two separate occasions in the
morning. Daily 40–80 mg valsartan as a
starting dose was administered, and then
thedosewereaugmentedtodaily80–160
mg according to the blood pressure in an
intention-to-treat manner. At baseline
and after 3 months the items shown in
Table 1 were examined. After the subjects
rested for 15 min in the supine position,
blood samples were drawn for the mea-
surements. Plasma samples collected
carefully and processed to avoid cold ac-
tivationwereincubatedat37°Cforanad-
equatelengthoftime,andtheangiotensin
I generated was measured by radioimmu-
noassay.Responderstovalsartanwerede-
ﬁned by a strict criterion (subjects who
had a decrease in DBP of 5 mmHg) and
a standard criterion (responders by the
strict criteria and subjects who achieved a
SBP of 140 mmHg and a DBP of 90
mmHg). The study was approved by the
ethicscommitteeofFukuiUniversity(no.
13-1, 14-2), and informed consent for
participation was obtained from all
individuals.
Genotyping
GenomicDNAwasisolatedbyacommer-
cial kit (QIAamp DNA Blood Mini Kit;
Qiagen,Tokyo,Japan)fromwholeblood.
In all DNA ampliﬁcation, a thermal cycler
(PC-700; Astec, Fukuoka, Japan) was
used, and PCR were performed funda-
mentally according to the protocol
(rTAQ, Toyobo, Osaka, Japan).
The renin (REN) C-5312T was as-
sayed by PCR-restriction fragment-length
polymorphism (RFLP) with DdeI diges-
tion. Primers as originally designed by us
from the adjacent sequence (11) were the
following: sense oligo 5-CGTAGTGC-
CATTTTTAGGAAC-3 and antisense
oligo 5-AACACCAAAGCAGGCTTAA-
3. The program consisted of 40 cycles of
denaturation at 94°C for 40 s, annealing
at52°Cfor40s,andextensionat72°Cfor
40 s followed by a ﬁnal extension at 72°C
for 5 min. PCR products were incubated
with DdeI overnight at 37°C. The PCR
products were loaded on 3.0% agarose
gels. Alleles were designated C or T, indi-
cating digestion by DdeI or not.
The ACE gene polymorphism was as-
sayed by DNA ampliﬁcation followed by
conﬁrmation with insertion-speciﬁc
primers. Primers were the same as those
in a previous report with minor modiﬁca-
tions (12). To conﬁrm the absence of in-
sertion allele, samples from the DD
genotype were subjected to an indepen-
dent DNA ampliﬁcation with an insertion
allele–speciﬁc primer. Primers were the
same as those in a previous report with
minor modiﬁcations (13). Alleles were
designated I or D, indicating the presence
or absence of the insertion sequence.
AGT M235T was assayed by mis-
match primer PCR-RFLP with SfaNI di-
gestion.Primerswerethesameasthosein
a previous report with minor modiﬁca-
tions(14).AllelesweredesignatedMorT,
indicating digestion by SfaNI or not.
AT1 A1166C was assayed by PCR-
RFLP with DdeI digestion. Primers were
the same as those in a previous report
with minor modiﬁcations (7). Alleles
were designated C or A, indicating diges-
tion by DdeI or not.
AT2 C3123A was assayed by PCR-
RFLP with AluI digestion. Primers were
the same as those in a previous report
with minor modiﬁcations (15). Alleles
were designated A or C, indicating diges-
tion by AluI or not. Because the AT2 gene
is harbored on the X chromosome, alleles
wereAorCinmenandAAorACorCCin
women, respectively.
Statistical analysis
The sample size of the study was calcu-
lated, assuming an SD for DBP of 10
mmHgandadifferencetobedetectedbe-
tween groups of at least 5 mmHg, and
usedabilateralpairedStudent’sttestwith
protection against type I error of 5 and
80% of power. It was calculated that the
study required 200 subjects in total. Sta-
tistical analyses were performed with
SPSS (version 11.0J; SPSS Japan, Tokyo,
Japan). Data are presented as numbers,
percentages,meansSD,ormedians(in-
terquartile ranges) as appropriate. The
differences between two paired continu-
ous variables for before and after admin-
istration of valsartan were analyzed by
Student’s t test or Wilcoxon’s signed-rank
test as appropriate. The difference for the
interactive effect of valsartan and geno-
type in subjects on blood pressure was
Table 1—Baseline characteristics of subjects and effects of valsartan
Baseline After administration P*
Blood pressure (mmHg)
SBP 162.4  18.2 144.8  18.4 0.001
DBP 95.1  13.6 86.4  12.2 0.001
Natrium (mEq/l) 141.4  2.0 141.3  2.3 0.51
Kalium (mEq/l) 4.02  0.35 4.06  0.35 0.12
Chlorine (mEq/l) 104.5  2.4 104.8  2.5 0.04
Creatinine (mg/dl) 0.75  0.28 0.74  0.27 0.07
Urinary natrium (mEq/creatinine) 171.3 (104.9–254.1) 187.3 (123.9–264.6) 0.07
Urinary kalium (mEq/creatinine) 49.8 (36.1–76.4) 54.7 (36.1–76.7) 0.03
Urinary chlorine (mEq/creatinine) 185.5 (116.1–269.1) 193.6 (141.0–288.7) 0.09
Urinary albumin excretion
(mg/creatinine)
25.0 (11.4–74.4) 14.9 (8.8–45.0) 0.001
Plasma renin activity (ng   ml
1  h
1) 0.60 (0.21–0.90) 1.10 (0.60–2.30) 0.001
Angiotensin I (pg/ml) 61.0 (39.5–110.0) 93.0 (55.0–210.0) 0.001
Angiotensin II (pg/ml) 5.0 (4.0–8.0) 7.0 (4.0–13.0) 0.001
Plasma aldosterone concentration
(pg/ml)
69.6 (50.0–100.0) 58.0 (39.9–76.7) 0.001
Atrial natriuretic peptide (pg/ml) 25.6 (17.0–39.5) 22.7 (14.7–34.3) 0.001
Data are means  SD or medians (interquartile ranges). *The differences between two paired continuous
variables for before and after administration of valsartan were analyzed by Student’s t test or a Wilcoxon
signed-rank test as appropriate. All P values are two-sided.
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ANOVA. Dichotomous and polychoto-
mous characteristics were compared with
use 
2 analysis for tests for Hardy-
Weinbergequilibriumandresponderand
sex distributions in REN C-5312T geno-
types. The differences between continu-
ous characteristics of genotype groups
were assessed by one-way ANOVA or a
Mann-Whitney U test was used as appro-
priate. Crude odds ratios (ORs) and 95%
CI for responders to valsartan were calcu-
lated using logistic regression for each
dichotomous characteristic. Then, multi-
variate logistic regression was performed
to adjust for potential confounding fac-
tors for responders to valsartan. All P val-
ues are two-sided.
RESULTS
Effects of valsartan on clinical
characteristics
A total of 231 subjects received mono-
therapy with valsartan for 3 months and
completed the study. Two patients
dropped out because of palpitation or
malaise. However, including these two
patients, no serious adverse effects oc-
curredinthestudyterm.Changesinclin-
ical and biochemical characteristics with
valsartan administration are summarized
in Table 1. Signiﬁcant reductions in sys-
tolic and DBP were achieved. Blood pres-
sure changes induced by valsartan
treatment showed unimodal distribution
(SBP[meanSD]17.618.5mmHg,
kurtosis 1.582, and skewness 0.496;
DBP8.411.4mmHg,kurtosis1.221,
and skewness 0.236). Urinary albumin
excretion was signiﬁcantly reduced from
a median of 25.0 to 14.9 mg/creatinine,
an 	40% reduction. Signiﬁcant eleva-
tions of plasma renin activity, plasma an-
giotensin I concentration, and plasma
angiotensin II concentration were ob-
served, whereas signiﬁcant reductions in
theplasmaaldosteroneconcentrationand
plasma atrial natriuretic peptide concen-
trationwereobserved.Theresponderrate
is calculated to be 71.0% (164 of 231
cases), according to the standard criteria
forthisstudyand63.2%(146of231sub-
jects) according to the strict criteria for
this study.
Genetic variants of the RAS and
reduction in blood pressure with
valsartan
Changes in blood pressure with valsartan
monotherapy in each genetic variation of
the RAS are summarized in Table 2. The
distributions of each genotype were sim-
ilar to those expected from Hardy-
Weinberg equilibrium. Among the
genetic variants of RAS elucidated, the
change in DBP was signiﬁcantly different
according to the genetic variant of renin
C-5312T: CC (n  81) from 95.9  12.9
to85.211.4mmHgversusCT/TT(n
150) from 94.7  14.0 to 87.7  12.6
mmHg (P  0.02 for the interactive effect
of valsartan and genotype on DBP). Thus,
it was revealed that the reductions in DBP
inCallelehomozygotesweresigniﬁcantly
largerthanthoseinTallelecarrierswitha
differenceofabout3.6mmHg(CC10.7
vs. CT/TT 7.1). The responder rate by
the strict criteria for C allele homozygotes
was signiﬁcantly larger than that for other
genotypes (CC 59 of 81 subjects [72.8%]
vs. CT/TT 87 of 150 subjects [58.0%];

2  4.98, P  0.03).
Genetic variants of REN C-5312T
and characteristics at baseline and
changes from baseline
The baseline demographic, clinical, and
biochemicalcharacteristicsofthesubjects
were almost balanced among genotypes
of REN C-5312T except for differences in
the serum chlorine level and in urinary
albumin excretion, including the doses of
valsartan and the duration of administra-
tion.Unexpectedly,nodifferencewasob-
served in levels of plasma renin activity,
angiotensin I, angiotensin II, or plasma
aldosterone. The drug doses of all geno-
types also balanced (data not shown).
Logistic regression analysis for
responders to valsartan
Univariateanalysiswasperformedamong
dichotomous variables of the subjects to
determine the predictors for responders
to valsartan (Table 3). The analysis
showed that high SBP and DBP, diabetes,
high plasma aldosterone concentration,
andCallelehomozygoteofRENC-5312T
were univariate predictors for responders
tovalsartan.Consequently,amultivariate
logistic regression was performed with
the four variables shown in Table 4. Con-
sidering that the criteria for the respond-
Table 2—Genetic variants of the RAS and reduction in blood pressure*
Genetic variants allele
(no.)
SBP (mmHg)
P*
DBP (mmHg)
P* Baseline Valsartan Baseline Valsartan
REN C-5312T 0.07 0.02
CC (81) 162.5  19.7 141.9  17.5 95.9  12.9 85.2  11.4
CT/TT (150) 162.4  17.5 146.4  18.8 94.7  14.0 87.7  12.6
ACE insertion/deletion 0.45 0.54
II (96) 162.9  19.6 146.4  17.6 94.8  14.8 85.9  13.7
ID/DD (135) 162.1  17.3 143.7  19.0 95.4  12.8 87.4  11.0
AGT M235T 0.87 0.25
TT (160) 161.7  17.9 144.3  18.5 95.4  13.5 86.5  11.9
MM/MT (71) 163.9  19.1 146.1  18.2 94.6  14.1 87.6  12.9
AT1 A1166C (AA) 0.50 0.52
AA (195) 162.3  18.6 144.8  18.9 94.7  13.8 86.1  12.5
AC/CC (36) 162.9  16.4 145.2  16.3 97.8  12.9 90.5  9.7
AT2 C3123A 0.37 0.14
C/CC(105) 162.3  17.8 143.5  17.3 95.7  13.6 86.1  12.0
A/AA/AC(126) 162.6  18.7 146.0  19.3 94.7  13.7 87.4  12.3
DataaremeansSD.Statisticalanalysisofthedifferencewasperformedbytwo-wayrepeated-measuresANOVA.*APvaluewascalculatedforthestatisticsshowing
the interactive effect of valsartan administration and category in patients on DBP.
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collinearity between SBP and DBP is as-
sumed, DBP was excluded from the ﬁnal
model of the analysis. Only high SBP, C
allele homozygote of REN C-5312T, and
diabetes were conﬁrmed to be indepen-
dent predictors for responders to valsar-
tan. In particular, there was a twofold
increase in the odds to be a responder for
subjects with the C allele homozygote of
REN C-5312T (OR 2.03 [95% CI 1.10–
3.74], P  0.02).
CONCLUSIONS — Theresultsofthe
present study revealed for the ﬁrst time
that a genetic variant of the human renin
gene, C-5312T, independently affects
the blood pressure reduction with angio-
tensinIIreceptorblockersinanadequate-
sized sample. As results with pharmaco-
genomic approaches in the area of
hypertension show, only a small fraction
of the genes probably contribute to the
antihypertensive responses. The genetic
loci for 
-adducin to diuretics and for 1-
adrenoceptor to -blocker have emerged
as strong candidates as one polymor-
phism for a speciﬁc class of antihyperten-
sive agents (16). The genetic variants of
the RAS are plausible candidates for the
pharmacogenomic predictors for ACE in-
hibitors and angiotensin II receptor
blockers and have been evaluated (17–
19). However, no consistent conclusions
were obtained regarding this issue, and
the problems contributing to the discor-
dance have been noted (10). Our study
was designed with the intention of avoid-
ing biases, especially those from sample
size for adequate power and adjustments
for confounding factors. To our knowl-
edge, only one study has analyzed the re-
lationship between genetic variants of the
RAS and angiotensin II receptor blockers
in an adequate-sized sample (206 sub-
jects)(18).Theseauthorsfoundnosignif-
icant association between the presence of
any genetic variant (ACE insertion/
deletion, angiotensinogen A-6G, AT1
A1166C, and AT1 C573T) and a reduc-
tion in blood pressure with concordance
to our results. However, no study regard-
ing the relationship of the renin gene to
the effects of angiotensin II receptor
blocker in an adequate-sized sample
other than our present study has been re-
ported thus far.
Recent advances in understanding of
the human renin gene revealed that mul-
tiple trans-factors and cis-elements are in-
volved in transcriptional regulation (20–
22). Germain et al. (23) showed that a
225-bp region located about 6 kb up-
stream from the transcription starting
point of the human renin gene gave 	57-
foldhighertranscriptionratesandisadis-
tal enhancer with human choriodecidual
cells. REN C-5312T was discovered as a
functional new polymorphism in the dis-
tal enhancer region of the human renin
gene(11).Thelevelsoftranscriptionwere
45% greater with the 5312T variant than
with the 5312C variant. Thus, the variant
wasvalidatedasafunctionalsinglenucle-
otide polymorphism. The results of the
present study demonstrated that C allele
homozygotes showed greater blood pres-
sure reduction with angiotensin II recep-
tor blockers than T allele carriers and,
thus, C allele homozygosity is a predictor
foraresponder.Onepossibleexplanation
is that C allele homozygotes might have
lower levels of renin and a sufﬁcient drug
effect compared with T allele carriers.
However, no difference in plasma renin
activity was observed between subjects
withthetwogenotypes.Analternativeex-
planationisthatthetranscriptionaldiffer-
ence demonstrated in the in vivo model
may not be reﬂected in the plasma level,
but the local concentration is different in
thetissueRAS.Recently,expressionofre-
nin in larger arteries outside the kidney
was shown with human renin gene pro-
moter/LacZ constructs for a trans-gene
model(24).Furthermore,afunctionalre-
ceptor for (pro)renin, which mediates
intracellular signaling by activating mito-
gen-activated protein kinases and extra-
cellular signal–regulated kinases 1 and 2
and acts as a cofactor by increasing the
efﬁciency of angiotensinogen cleavage,
Table 3—Univariate analysis of predictors for responder to valsartan
Variables (criteria, %) OR (95% CI) P
Age (65 years, 51.2%) 1.27 (0.74–2.16) 0.39
Sex (male, 43.7%) 0.94 (0.55–1.61) 0.82
BMI (25 kg/m
2, 38.3%)* 1.22 (0.70–2.13) 0.48
SBP (160 mmHg, 48.1%) 2.47 (1.42–4.31) 0.001
DBP (95 mmHg, 48.1%) 4.47 (2.48–8.05) 0.001
Diabetes (19.5%) 0.48 (0.25–0.93) 0.03
Dyslipidemia (27.4%) 1.15 (0.61–2.16) 0.67
Urinary albumin excretion (30 mg/g creatinine, 44.4%) 0.76 (0.44–1.31) 0.32
eGFR (60 ml/min per 1.73m
2, 20.8%) 0.85 (0.42–1.71) 0.64
Urinary natrium (170 mEq/creatinine, 50.2%) 1.28 (0.74–2.22) 0.37
Plasma renin activity (0.5 ng   ml
1   h
1, 56.3%) 1.08 (0.63–1.85) 0.77
ACE (15.0 IU/l, 38.3%) 1.22 (0.70–2.13) 0.48
Angiotensin I (50.0 pg/ml, 59.9%) 1.07 (0.59–1.93) 0.83
Angiotensin II (5.0 pg/ml, 48.7%) 1.63 (0.91–2.93) 0.10
Plasma aldosterone concentration (75.0 pg/ml, 44.6%) 1.83 (1.06–3.18) 0.03
Atrial natriuretic peptide (20.0 pg/ml, 69.5%) 0.77 (0.41–1.46) 0.42
REN C-5312T (CC, 35.1%) 1.94 (1.08–3.49) 0.03
ACE deletion/insertion (II, 41.6%) 0.95 (0.55–1.63) 0.85
AGT M235T (TT, 69.3%) 1.08 (0.61–1.92) 0.80
AT1 A1166C (AA, 84.4%) 0.84 (0.39–1.77) 0.64
AT2 C3123A (C/CC, 45.5%) 1.53 (0.89–2.64) 0.12
Crude ORs for responder to valsartan and 95% CIs were calculated using logistic regression for each
dichotomous characteristic. Responders to valsartan were deﬁned as subjects who had a decrease in DBP of
5 mmHg. *BMI is the weight in kilograms divided by square of the height in meters.
Table 4—Multivariate logistic regression analysis for responder to valsartan
 SE Wald’s 
2 OR (95% CI) P
SBP (160 mmHg) 0.91 0.29 9.79 2.49 (1.41–4.42) 0.002
REN C-5312T (CC) 0.71 0.31 5.10 2.03 (1.10–3.74) 0.02
Diabetes 0.74 0.35 4.36 0.48 (0.24–0.96) 0.04
Plasma aldosterone concentration
(75.0 pg/ml)
0.54 0.29 3.42 1.72 (0.97–3.07) 0.06
Multivariate logistic regression was performed to adjust for potential confounding factors for responders to
valsartan.ResponderstovalsartanweredeﬁnedassubjectswhohadadecreaseinDBPof5mmHgormore.
All factors in this table were included in the ﬁnal model.
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discoveries raise the possibility that tissue
renin expression exerts a signiﬁcant effect
on the tissue RAS and relates to the phar-
macogenetic effects of the C-5312T vari-
ant in our study. On the other hand, one
plausible supposition is that blood pres-
sure reduction is larger in the 5312T vari-
ant than in C allele homozygotes.
However, the results were different. We
supposed that 160 mg valsartan daily,
the approved maximal dose in Japan,
might not be sufﬁcient for T allele car-
riers. We also demonstrated an upregu-
lation of renal tissue RAS with ACE
expression (3). This would be one ex-
planation for the fact that diabetes is an
independent predictor for nonre-
sponders at a twofold OR.
Several limitations of this study
should be noted. We have calculated the
sample size considering a type I error of 5
and 80% power; however, the sample
number is still relatively small. In partic-
ular, the power calculation was not sufﬁ-
cient for AT1 because of a small number
for minor alleles in 36 of 231 subjects.
Although population admixture is
thought to contribute to concordant re-
sults among studies, our study comprises
onlyaJapanesepopulation.Weevaluated
ﬁve independent genetic variants. Ac-
cordingly, a correction for multiple test-
ing might be needed. On this point, the P
value threshold of 0.05 for signiﬁcance
might be relatively large. Another limita-
tion is that only one genetic variant for
each gene was assayed.
In summary, this study provides
strongsupportthatageneticvariantofthe
renin gene, C-5312T, and diabetes con-
tribute to the effects of angiotensin II re-
ceptor blockers. In other words, the
variant is able to be an independent pre-
dictor for a responder to an angiotensin II
receptor blocker. Thus, a new possibility
forpersonalizedmedicinebygeneticvari-
ants of the RAS has been shown in treat-
ment of hypertension with angiotensin
II receptor blockers. Further studies are
needed, including studies on other sin-
gle nucleotide polymorphisms in each
gene to be able to generalize the results
to other races and evaluate prorenin
concentrations.
Acknowledgments— This work was sup-
ported by Grants-in-Aid 08770879,
09770843, and 14571020 from the Ministry
of Education, Science and Culture of Japan
and by the Program for Promotion of Funda-
mentalStudiesinHealthSciencesoftheNational
Institute of Biomedical Innovation (05-21).
No potential conﬂicts of interest relevant to
this article were reported.
Parts of this study were presented in ab-
stract form at the 69th Scientiﬁc Sessions of
the American Diabetes Association, New Or-
leans, Louisiana, 5–9 June 2009.
WearegratefultoProfessorHiroyukiNaka-
mura (Department of Environmental and Pre-
ventive Medicine, Graduate School of Medical
Science, Kanazawa University) for his advice
on the statistical analysis and to the study in-
vestigators of the Genomic Disease Outcome
Consortium (G-DOC), which was organized
astheKanazawaRenalDiseaseStudyGroupin
1995 for presenting a part of the subjects of
this study. We are also grateful to Youko Ha-
yashida for secretarial assistance.
References
1. Corvol P, Soubrier F, Jeunemaitre X. Mo-
lecular genetics of the renin-angiotensin-al-
dosterone system in human hypertension.
Pathol Biol (Paris) 1997;45:229–239
2. Wakahara S, Konoshita T, Mizuno S, Mo-
tomura M, Aoyama C, Makino Y, Kato N,
KoniI,MiyamoriI.Synergisticexpression
of angiotensin-converting enzyme (ACE)
and ACE2 in human renal tissue and con-
founding effects of hypertension on the
ACE to ACE2 ratio. Endocrinology 2007;
148:2453–2457
3. Konoshita T, Wakahara S, Mizuno S, Mo-
tomuraM,AoyamaC,MakinoY,KawaiY,
Kato N, Koni I, Miyamori I, Mabuchi H.
Tissuegeneexpressionofrenin-angiotensin
system in human type 2 diabetic nephrop-
athy. Diabetes Care 2006;29:848–852
4. Cambien F, Poirier O, Lecerf L, Evans A,
Cambou JP, Arveiler D, Luc G, Bard JM,
Bara L, Ricard S, Tiret L, Amouyel P, Al-
henc-Gelas F, Soubrier F. Deletion poly-
morphism in the gene for angiotensin-
converting enzyme is a potent risk factor
for myocardial infarction. Nature 1992;
359:641–644
5. KonoshitaT,MiyagiK,OnoeT,KatanoK,
Mutoh H, Nomura H, Koni I, Miyamori I,
Mabuchi H. Effect of ACE gene polymor-
phism on age at renal death in polycystic
kidney disease in Japan. Am J Kidney Dis
2001;37:113–118
6. Jeunemaitre X, Soubrier F, Kotelevtsev
YV, Lifton RP, Williams CS, Charru A,
Hunt SC, Hopkins PN, Williams RR, La-
louel JM, Pierre C. Molecular basis of
human hypertension: role of angio-
tensinogen. Cell 1992;71:169–180
7. Bonnardeaux A, Davies E, Jeunemaitre X,
Fery I, Charru A, Clauser E, Tiret L, Cam-
bien F, Corvol P, Soubrier F. Angiotensin
II type 1 receptor gene polymorphisms in
human essential hypertension. Hyperten-
sion 1994;24:63–69
8. Brenner BM, Cooper ME, de Zeeuw D,
Keane WF, Mitch WE, Parving HH, Re-
muzziG,SnapinnSM,ZhangZ,Shahinfar
S. Effects of losartan on renal and cardio-
vascular outcomes in patients with type 2
diabetes and nephropathy. N Engl J Med
2001;345:861–869
9. Julius S, Kjeldsen SE, Weber M, Brunner
HR, Ekman S, Hansson L, Hua T, Laragh
J, McInnes GT, Mitchell L, Plat F, Schork
A, Smith B, Zanchetti A. Outcomes in hy-
pertensive patients at high cardiovascular
risk treated with regimens based on val-
sartan or amlodipine: the VALUE ran-
domised trial. Lancet 2004;363:2022–
2031
10. Farahani P, Dolovich L, Levine M. Ex-
ploring design-related bias in clinical
studies on receptor genetic polymor-
phism of hypertension. J Clin Epide-
miol 2007;60:1–7
11. Fuchs S, Philippe J, Germain S, Mathieu
F,JeunemaitreX,CorvolP,PinetF.Func-
tionality of two new polymorphisms in
the human renin gene enhancer region.
J Hypertens 2002;20:2391–2398
12. Rigat B, Hubert C, Corvol P, Soubrier F.
PCR detection of the insertion/deletion
polymorphism of the human angiotensin
converting enzyme gene (DCP1) (dipep-
tidyl carboxypeptidase 1). Nucleic Acid
Res 1992;20:1433
13. Lindpaintner K, Pfeffer MA, Kreutz R,
Stampfer MJ, Grodstein F, LaMotte F,
Buring J, Hennekens CH. A prospective
evaluation of an angiotensin-converting-
enzyme gene polymorphism and the risk
of ischemic heart disease [see comments].
N Engl J Med 1995;332:706–711
14. Caulﬁeld M, Lavender P, Farrall M, Mu-
nroe P, Lawson M, Turner P, Clark AJ.
Linkage of the angiotensinogen gene to
essential hypertension [see comments].
N Engl J Med 1994;330:1629–1633
15. KatsuyaT,HoriuchiM,MinamiS,KoikeG,
Santoro NF, Hsueh AJ, Dzau VJ. Genomic
organization and polymorphism of human
angiotensin II type 2 receptor: no evidence
for its gene mutation in two families of hu-
man premature ovarian failure syndrome.
Mol Cell Endocrinol 1997;127:221–228
16. Johnson JA, Turner ST. Hypertension
pharmacogenomics: current status and
future directions. Curr Opin Mol Ther
2005;7:218–225
17. Kurland L, Liljedahl U, Karlsson J, Kahan
T, Malmqvist K, Melhus H, Syvanen AC,
Lind L. Angiotensinogen gene polymor-
phisms:relationshiptobloodpressurere-
sponse to antihypertensive treatment.
Results from the Swedish Irbesartan Left
Ventricular Hypertrophy Investigation vs
Atenolol (SILVHIA) trial. Am J Hypertens
2004;17:8–13
18. Redon J, Luque-Otero M, Martell N,
Chaves FJ. Renin-angiotensin system
gene polymorphisms: relationship with
blood pressure and microalbuminuria in
telmisartan-treatedhypertensivepatients.
Pharmacogenomics J 2005;5:14–20
Konoshita and Associates
DIABETES CARE, VOLUME 32, NUMBER 8, AUGUST 2009 148919. Parving HH, de Zeeuw D, Cooper ME,
Remuzzi G, Liu N, Lunceford J, Shahinfar
S, Wong PH, Lyle PA, Rossing P, Brenner
BM. ACE gene polymorphism and losar-
tan treatment in type 2 diabetic patients
with nephropathy. J Am Soc Nephrol
2008;19:771–779
20. Konoshita T, Germain S, Philippe J,
Corvol P, Pinet F. Evidence that renal
and chorionic tissues contain similar
nuclear binding proteins that recognize
the human renin promoter. Kidney Int
1996;50:1515–1524
21. Konoshita T, Makino Y, Wakahara S, Ido
K, Yoshida M, Kawai Y, Miyamori I. Can-
didate cis-elements for human renin gene
expression in the promoter region. J Cell
Biochem 2004;93:327–336
22. Konoshita T, Fuchs S, Makino Y, Waka-
haraS,MiyamoriI.Aproximaldirectrepeat
motif characterized as a negative regulatory
elementinthehumanreningene.JCellBio-
chem 2007;102:1043–1050
23. Germain S, Bonnet F, Philippe J, Fuchs S,
Corvol P, Pinet F. A novel distal enhancer
confers chorionic expression on the hu-
man renin gene. J Biol Chem 1998;273:
25292–25300
24. Fuchs S, Germain S, Philippe J, Corvol P,
Pinet F. Expression of renin in large arter-
ies outside the kidney revealed by human
renin promoter/LacZ transgenic mouse.
Am J Pathol 2002;161:717–725
25. Nguyen G, Delarue F, Burckle C,
Bouzhir L, Giller T, Sraer JD. Pivotal
role of the renin/prorenin receptor in an-
giotensin II production and cellular re-
sponses to renin. J Clin Invest 2002;109:
1417–1427
Renin gene variant and response to ARBs
1490 DIABETES CARE, VOLUME 32, NUMBER 8, AUGUST 2009